Tee Labs Incubatee: ShouTi Successfully Raises $100 Million in Series B Financing

Tee Labs Incubatee: ShouTi Successfully Raises $100 Million in Series B Financing，Leveraging Advanced Computational and Structure-Based Drug Design Platform to Accelerate the Development of Life-Changing Medicines for Patients

ShouTi Inc., a clinical-stage biopharmaceutical company, is dedicated to developing life-changing medicines for patients by leveraging advanced computational and structure-based technologies. The company announced on October 20th the completion of a $100 million Series B financing round led by BVF Partners L.P. (BVF). Other new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners LP, as well as co-founder and strategic partner Schrödinger. The company’s existing investors, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital, and WuXi AppTec, also participated in this round. Following this financing, Jessica Lifton of BVF and Dr. Chen Yu of TCG X have joined ShouTi’s Board of Directors.

Upon the completion of the Series B financing, ShouTi has raised a total of $158 million. The proceeds will be used to advance the company’s drug discovery platform. This platform integrates advanced computational chemistry, world-leading structural biology, and large-scale data integration to design oral medicines that can overcome the limitations of current biologics and peptide drugs and possess superior properties. This financing will also drive the continued development of the company’s clinical-stage product pipeline, focusing on chronic diseases with high unmet clinical needs, such as cardiovascular, metabolic, and pulmonary diseases.

Dr. Raymond Stevens, CEO of ShouTi, stated: “Over the past 20 years, biologics and peptide drugs have advanced rapidly, and significant progress has also been made in computational prediction and experimental methods. ShouTi is now integrating these state-of-the-art scientific technologies to develop more effective oral small molecule drugs to alleviate pain and improve the quality of life for a broader patient population.”

ShouTi’s drug discovery and development engine is built upon its more than two decades of innovative experience in generating membrane protein structures. It focuses on one of the most challenging target classes in structure-based drug discovery—G-protein coupled receptors (GPCRs). ShouTi is leveraging high-resolution structures to better understand and modulate pharmacological effects through chemical design. With these advantages, ShouTi’s platform can transform biologic and peptide therapies into oral small molecule drugs with better properties, enhanced bioavailability, and improved stability. By developing oral medicines with superior properties, reducing logistical burdens and the economic burden on patients, ShouTi is uniquely positioned to address the unmet needs of chronic disease treatments on a global scale.

Mark Lampert, Founder and CEO of BVF, stated: “We are incredibly proud to lead ShouTi’s Series B financing and support them in advancing the treatment of chronic diseases by converting biologics and peptide drugs into oral small molecule medicines.”

Chen Yu, Managing Partner of TCG X, stated: “ShouTi’s investment in data integration and next-generation computational chemistry has empowered its discovery engine. This engine focuses on finding the best medicines for validated targets, while eliminating biological risks and accelerating development. We look forward to continuing our strong support for the ShouTi team as they develop superior therapies for patients worldwide.”

ShouTi has an experienced team of drug discovery and development personnel, industry leaders, and experts, renowned in the field of structure-based GPCR-targeted drug discovery. The company’s team has accumulated deep experience in complex biological targets and mechanisms, and has led the discovery, development, and commercialization of multiple drugs. ShouTi’s CEO, Dr. Stevens, is a pioneer in the field of high-throughput structural drug discovery and has founded several successful biotech companies, including Syrrx, which developed Nesina®, a drug for type 2 diabetes, and Receptos, which developed Zeposia®. Zeposia® is a GPCR-targeted drug recently approved for the treatment of multiple sclerosis and ulcerative colitis. The team led by Dr. Stevens includes:

  • Dr. Mark Bach, Chief Medical Officer
  • Dr. Michael Hanson, Chief Technology Officer
  • Melita Sun Jung, Chief Business Officer
  • Dr. Xichen Lin, Chief Scientific Officer and General Manager of ShouTi Shanghai
  • Jun Yoon, Chief Operating Officer

SVB Leerink served as the exclusive financial advisor to ShouTi for the Series B financing.

About ShouTi

ShouTi develops life-changing medicines for patients using advanced computational and structure-based technologies. The company’s drug discovery platform integrates the latest advancements in computational chemistry, visualization of molecular interactions, and intelligent data integration to design superior oral medicines that overcome the limitations of current biologics and peptide drugs. ShouTi is advancing a pipeline of differentiated, clinical-stage therapies focused on chronic diseases with high unmet needs, such as cardiovascular, metabolic, and pulmonary diseases. The ShouTi team has deep experience in complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development, and is committed to realizing the company’s vision: to design and develop world-class medicines that can significantly improve patient outcomes and have broad commercial potential. For more information, please visit www.shoutipharma.com and follow the company on Twitter @ShouTiPharma and LinkedIn.

About Tee Labs

Tee Labs is an industrial incubator, wholly-owned and independently operated by TF Capital, dedicated to advancing pioneering medical fields such as new drug discovery, diagnostics, and personalized medicine that incorporate artificial intelligence and digital solutions. Tee Labs provides comprehensive support—including R&D facilities, corporate services, supply chain integration, and financial backing—to deeply empower entrepreneurial teams and accelerate their R&D progress. The laboratories are equipped with basic, general-purpose experimental equipment and shared equipment platforms, significantly shortening the setup phase for startups in terms of facilities and equipment, allowing them to focus on their core R&D work.